Merck & Co., Inc. (MRK)
Merck & Co., Inc. (MRK) is a global healthcare company specializing in pharmaceuticals, vaccines, and biologic therapies. Founded in 1891, it is known for developing innovative medicines across various therapeutic areas including oncology, infectious diseases, cardiology, and immunology. Merck focuses on research and development to improve health outcomes worldwide.
Dividend History
Investors can expect a dividend payout of $0.85 per share, scheduled to be distributed in 48 days on January 8, 2026
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| January 8, 2026 | $0.85 | 2025-12-15 | 2025-12-15 |
| October 7, 2025 | $0.81 | 2025-09-15 | 2025-09-15 |
| July 8, 2025 | $0.81 | 2025-06-16 | 2025-06-16 |
| April 7, 2025 | $0.81 | 2025-03-17 | 2025-03-17 |
| January 8, 2025 | $0.81 | 2024-12-16 | 2024-12-16 |
Dividends Summary
- Merck & Co., Inc. has issued 89 dividend payments over the past 22 years
- The most recent dividend was paid 45 days ago, on October 7, 2025
- The highest dividend payed out to investors during this period was $0.85 per share
- The average dividend paid during this period was $0.50 per share.
Company News
Healthcare stocks are experiencing a sector rotation as investors move away from tech, with three large-cap pharmaceutical companies showing strong potential due to attractive valuations, breakthrough drugs, and promising earnings.
Jim Cramer labeled Recursion Pharmaceuticals a meme stock, but evidence suggests otherwise. The biotech company uses AI for drug discovery, has promising partnerships, but remains a speculative and risky investment with no market products.
Merck reported positive Phase 2 CADENCE study results for Winrevair in treating combined pulmonary hypertension, showing significant reduction in pulmonary vascular resistance and a consistent safety profile.
The global cell harvesting market is projected to grow from $5.94 billion in 2024 to $20.08 billion by 2034, with a 12.95% CAGR, driven by increasing demand for regenerative medicine, cell-based therapies, and technological advancements in cell research.
Merck's stock has underperformed the industry, sector, and S&P 500 this year due to various challenges, including the upcoming patent expiration of its blockbuster drug Keytruda in 2028 and declining sales of its Gardasil vaccine in China. However, the company has a promising pipeline and new products that could drive long-term growth.
